Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Ovarian Neoplasms 9Triple Negative Breast Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 5Esophageal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2NSCLC 2Mouth Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Ovarian Epithelial 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thyroid Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Solid Tumor Cancer 1Sarcoma, Kaposi 1Respiratory Tract Neoplasms 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-Resistant Primary Peritoneal Carcinoma 1Pancreatic Intraductal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1

Interventions

Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Squamous Non-small Cell Lung Cancer × Paclitaxel × Clear all
NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
480 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡